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Polycyclic aromatic hydrocarbons (PAHs) are 
an environmentally ubiquitous class of com-
pounds that are formed during incomplete 
combustion of organic substances. Several 
PAHs have been classified as probable human 
carcinogens (Boffetta et al. 1997; Shimada 
2006). In the general population, the major 
source of exposure is tobacco smoke (Lioy 
and Greenberg 1990), with diet (grilled/
smoked foods, cereals, and leafy green veg-
etables) and exposure to fossil fuel combus-
tion by-products contributing to cumulative 
exposure (Waldman et al. 1991). Although 
there is strong evidence for the relationship 
between PAH exposure and lung, skin, and 
bladder cancer in humans, it is equivocal as 
to whether PAH exposure is associated with 
breast cancer (Boffetta et al. 1997; Gammon 
and Santella 2008; Shimada 2006).
PAH–DNA adducts reflect not only 
PAH exposure but also the body’s ability to 
metabolize these compounds. The forma-
tion of these carcinogen–DNA adducts is 
recognized as a key event in the initiation of 
carcinogenesis (Gammon et al. 2004b; Hecht 
2003; Wogan et al. 2004). In the Long Island 
Breast Cancer Study Project (LIBCSP), a large 
population-based case–control study, blood 
levels of PAH–DNA adducts were associated 
with a modest 29–35% elevation in breast 
cancer risk among women (Gammon et al 
2004b). These findings are consistent with 
previously conducted, smaller hospital-based 
studies (Li et al. 1996, 2002; Rundle et al. 
2000a). Animal studies have provided fur-
ther support for the role of PAHs as mam-
mary carcinogens (Cavalieri et al. 1991; 
el-Bayoumy et al. 1995). Although a signifi-
cant association between breast cancer risk 
and detectable PAH–DNA adducts has been 
noted, a dose–response relationship was not 
observed in the LIBCSP. Further stratifica-
tion by known sources of PAH exposure, such 
as cigarette smoking or the consumption of 
PAH-containing foods, did not modify this 
association (Gammon et al. 2004b). These 
findings are consistent with those from smaller 
studies (Hu et al. 2007). The lack of a dose 
response effect suggests that there may be sub-
groups of women who are more genetically 
susceptible to the carcinogenic effects of PAH 
exposure on breast tissue.
Inherited differences in the metabolism of 
PAHs, interindividual differences in enzyme 
expression, and induction may be key determi-
nants in individual breast cancer susceptibility 
(Shimada 2006). Genetic differences in meta-
bolic activation and detoxification of PAHs 
have been shown to affect differences in phe-
notypic biomarkers such as urinary metabo  lites 
and are hypothesized to influence cancer risk 
(Brescia et al. 2004; Hatsukami et al. 2006; 
Hecht et al. 2006; Kuljukka-Rabb et al. 2002; 
Upadhyaya et al. 2006; Wogan et al. 2004). 
Further investigation of these genetic differ-
ences in the deactivation of PAH metabo-
lites may contribute to our understanding of 
the lack of a dose–response relationship and 
increased understanding of breast cancer risk.
The phase II metabolic super family of 
GST enzymes is involved in the metabolic 
activation and deactivation of PAH metabo-
lites, and polymorphisms in these genes lead 
to specific changes in enzyme function and 
the capacity to metabolize PAH compounds 
(Hecht 1999). The GSTM1 null polymor-
phism [GenBank BC036805; National Center 
for Biotechnology Information (NCBI) 2009a] 
results in the absence of isoenzyme (mu) 
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Ba c k g r o u n d: Polycyclic aromatic hydrocarbons (PAHs) may increase breast cancer risk, and 
the association may be modified by inherited differences in deactivation of PAH intermediates by 
glutathione S-transferases (GSTs). Few breast cancer studies have investigated the joint effects of 
multiple GSTs and a PAH biomarker. 
oB j e c t i v e: We estimated the breast cancer risk associated with multiple polymorphisms in the 
GST gene (GSTA1, GSTM1, GSTP1, and GSTT1) and the interaction with PAH–DNA adducts 
and cigarette smoking. 
Me t h o d s : We conducted unconditional logistic regression using data from a population-based 
sample of women (cases/controls, respectively): GST polymorphisms were genotyped using poly-
merase chain reaction and matrix-assisted laser desorption/ionization time-of-flight assays (n = 926 
of 916), PAH–DNA adduct blood levels were measured by competitive enzyme-linked immunosor-
bent assay (n = 873 of 941), and smoking status was assessed by in-person questionnaires (n = 943 
of 973). 
re s u l t s: Odds ratios for joint effects on breast cancer risk among women with at least three variant 
alleles were 1.56 [95% confidence interval (CI), 1.13–2.16] for detectable PAH–DNA adducts and 
0.93 (95% CI, 0.56–1.56) for no detectable adducts; corresponding odds ratios for three or more 
variants were 1.18 (95% CI, 0.82–1.69) for ever smokers and 1.44 (95% CI, 0.97–2.14) for never 
smokers. Neither interaction was statistically significant (p = 0.43 and 0.62, respectively). 
co n c l u s i o n: We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, 
GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.
key w o r d s : breast cancer, GST, Long Island, PAH–DNA adducts, smoking. Environ Health 
Perspect 117:552–558 (2009).  doi:10.1289/ehp.0800119 available via http://dx.doi.org/ [Online 
10 December 2008]PAH–DNA adducts, GSTs, and breast cancer
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expression and reduced glutathione binding 
efficiency of PAH epoxides and other geno-
toxic substrates (Hayes and Pulford 1995). 
The GSTP 1le105Val polymorphism [GSTP1; 
Unigene Hs.523836 (NCBI 2009b)] is associ-
ated with reduced isoenzyme (pi) expression 
and a reduced capacity to inactivate carcino-
gens, including the diol epoxides created dur-
ing phase I metabolism of PAHs (Coles and 
Kadlubar 2003; Pavanello and Clonfero 2000; 
Ryberg et al. 1997; Watson et al. 1998). 
The GSTT1 null polymorphism (Genbank 
X79389) results in the absence of (theta) isoen-
zyme (Hayes and Pulford 1995), but the role of 
this polymorphism in relation to PAH metabo-
lism is uncertain (Pavanello and Clonfero 
2000). On the one hand, the theta isoenzyme 
is thought to activate alkylating agents, such as 
nitrosamines present in tobacco smoke (Hecht 
1999; Pavanello and Clonfero 2000); on the 
other hand, in human erythrocytes, the theta 
isoenzyme binds reactive conjugates to gluta-
thione, inhibiting genotoxic damage to DNA 
(Pelin et al. 1996). GSTs conjugate PAH diol 
epoxides into water-soluble products, and GST 
enzymes also protect against products of oxida-
tive stress (Mitrunen and Hirvonen 2003). 
GSTA1 (Unigene Hs. 446309) is thought to 
decrease reactive oxygen species and, via an 
increase in antioxidant levels, to also play an 
active role in PAH metabolism (Ahn et al. 
2006; Coles et al. 2005; Korashy and El-Kadi 
2006). For GSTA1, two alleles, hGSTA1*A and 
hGSTA1*B, differ in three linked base changes 
in the 5´ promoter region of the gene: T→G 
at nucleotide 567, C→T at nucleotide 69, and 
G→A at nucleotide 52 (Coles et al 2001a, 
2001b). These substitutions result in differen-
tial expression (Coles et al. 2001b), with lower 
transcriptional activation with GSTA1*B (vari-
ant) than with GSTA1*A (common) alleles. 
It has been demonstrated by our group that 
the variant GSTA1*B/B genotype is associated 
with higher risk of breast cancer among smok-
ers compared with nonsmokers with the A/A* 
genotype (Ahn et al. 2006).
Only one breast cancer study (Rundle et al. 
2000b) has reported on a potential interaction 
between GSTM1 null genotype and PAH–
DNA adducts. However, the sample size was 
small (< 100 cases), yielding unstable effect 
estimates and prohibiting exploration of more 
than one single nucleotide polymorphism from 
among the many that contribute to this com-
plex cascade of activation and detoxification. 
Investigating whether genetically determined 
differences in multiple GST genotypes mod-
ify the association between breast cancer risk 
and PAH exposure may improve our ability to 
identify women who are susceptible to the car-
cinogenic effects of PAHs on breast tissue.
The goal of our present analysis was to 
investigate whether multiple GST polymor-
phisms modified the relationship between 
PAH exposure and breast cancer, using the 
lymphocyte PAH–DNA adduct biomarker as 
our primary exposure measure of interest using 
a large, population-based sample of cases and 
controls from the LIBCSP. We also evaluated 
the interaction between GST polymorphisms 
and smoking status, because smoking behav-
ior was previously identified as the strongest 
predictor of detectable PAH–DNA adducts 
(Shantakumar et al. 2005). Finally, we inves-
tigated the joint effects of smoking status and 
GST polymorphisms on detectable PAH–
DNA adducts among control women.
Methods
Study population. The population-based sample 
of cases and controls from the LIBCSP has been 
described previously (Gammon et al. 2002a). 
Briefly, cases were defined as English-speaking 
adult women newly diagnosed with breast 
cancer residing in Nassau County or Suffolk 
County in Long Island, New York. Population-
based controls were identified through random-
digit dialing for women < 65 years of age, and 
by Health Care Finance rosters for women 
≥ 65 years of age within the same counties, 
and frequency matched them (by 5-year age 
groups) to cases. Participants were between 20 
and 98 years of age; 94% were white, 4% were 
black, and 2% other races/ethnicities. The study 
protocol was approved by the institutional 
review boards of the collaborating institutions, 
and written informed consent was obtained 
from the LIBCSP participants.
Data collection. Respondents to the case–
control interview included 1,508 cases and 1,556 
controls (Gammon et al. 2002a). The 2-hr in-
person structured interview collected data on 
history of cigarette smoking (current, past), 
exposure to environmental tobacco smoke in 
the residential home throughout the life course 
(Gammon et al. 2004a), and other characteristics 
potentially relevant to breast cancer risk. Blood 
samples were obtained from 73% of cases and 
73% of controls (Gammon et al. 2004b).
Laboratory assays. We processed the 
blood samples collected by Gammon et al. 
(2004b), isolated the DNA and completed 
genotyping for GSTT1 and GSTM1 as pre-
viously described (Steck et al. 2007b), by a 
multiplex polymerase chain reaction method 
as previously described (Bell et al. 1992). 
Genotyping for GSTP1 (Ile105Val; rs1695) 
(Steck et al. 2007b) and GSTA1 (Ahn et al. 
2006) was completed as previously described 
by matrix-assisted laser desorption/ioniza-
tion time-of-flight assay (Fannon 2002). We 
included positive and negative controls in 
each batch, and a random 10% repeated sam-
pling yielded a 97% concordance. Genotype 
distributions of GSTA1 (p = 0.81) and 
GSTP1 (p = 0.38) were in Hardy-Weinberg 
equilibrium among controls. The number of 
cases and controls, respectively, for whom 
genotyping was successful varied with geno-
type (n = 1,041 and 1,090 for GSTA1, 983 
and 1,016 for GSTT1, 975 and 1,001 for 
GSTM1, and 1,027 and 1,069 for GSTP1). 
Missing genotype data were primarily due 
to insufficient DNA (Ahn et al. 2006; Steck 
et al. 2007b).
PAH–DNA adducts were measured in 
peripheral mononuclear cell DNA using com-
petitive enzyme-linked immunosorbent assay as 
previously described (Gammon et al. 2002b). 
PAH–DNA adduct measurements were 
available for 873 cases and 941 controls who 
donated sufficient blood volume for the assay, as 
described previously (Gammon et al. 2004b).
Statistical methods. We calculated odds 
ratios (ORs) and 95% confidence intervals 
(CIs) using unconditional logistic regression 
using SAS version 9.0 (SAS Institute Inc., 
Cary, NC). All models were adjusted for 
age at reference (date of diagnosis for cases 
and date of identification for controls), the 
  frequency-matching factor. Covariates consid-
ered as potential confounders included race, 
family history of breast cancer, parity, age at 
menarche, age at first pregnancy, menopausal 
status, lifetime alcohol intake, education, and 
smoking status. We considered a covariate a 
confounder and included it in the models if it 
changed the ORs by more than 10% (Hosmer 
and Lemeshow 1989); however, adjustment 
by these potential confounders did not appre-
ciably change the ORs, and therefore only the 
age-adjusted estimates are shown.
For our first set of analyses, our goal was 
to determine whether breast cancer risk is 
associated with the GST polymorphisms and 
whether they interact with PAH exposures, 
either alone or jointly, to affect breast cancer 
risk. We previously reported that the ORs 
for the association between breast cancer and 
individual GST genotypes were not substan-
tially elevated (Ahn et al. 2006; Steck et al. 
2007b), although risk was elevated when we 
considered multiple GSTs (Ahn et al. 2006; 
Steck et al 2007b). Here, we focus primarily 
on the analyses that examine the interaction 
of GSTs with adducts and smoking, using the 
following methods.
We estimated the ORs for breast cancer 
in relation to potential interactions between 
various PAH measures and the GST polymor-
phisms, a) considering each polymorphism 
separately (Table 1), and (b) by grouping indi-
viduals based on the number of variant alleles 
for any of the four GST polymorphisms con-
sidered (Tables 2 and 3). For this group of 
analyses, the reference group included women 
with GSTT1 present, GSTM1 present, GSTP1 
common (AG or GG), or GSTA1 common 
(A/A*) genotypes. Using this approach, we 
explored the effect of even a single at-risk 
genotype, among those who carried com-
mon alleles for the other GSTs considered. McCarty et al.
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We chose to group the genes this way based 
on experimental evidence indicating reduced 
or no enzyme activity for the variant and 
null genotypes. In terms of metabolism, the 
GSTP1 valine genotype is thought to be asso-
ciated with lower glutathione S-transferase pi 
enzyme activity compared with the GSTP1 
isoleucine genotype, which plays a key role 
in the detoxification of benzo[a]pyrene 
diol epoxide, a major carcinogen present in 
tobacco smoke (Fields et al. 1998; Hecht 
1999; Nakajima et al. 1995). To explore these 
potential gene–PAH interactions, we devel-
oped separate models for women based on 
the presence or absence of the PAH exposure 
measure [PAH–DNA adducts (detectable/
not detectable); self-  reported cigarette smok-
ing status (ever/never, or current/past/never)] 
or pack years of smoking history (< 15 years, 
15–30 years, > 30 years). We also developed 
models for all women that included multi-
plicative inter  action terms (Hosmer and 
Lemeshow 1989); gene–environment inter-
actions were formally assessed by examining 
departures from multiplicity by comparing 
models with and without the interaction term 
using the likelihood ratio test (LRT) (Hosmer 
and Lemeshow 1989). In addition, we inves-
tigated potential interactions on the additive 
scale (Hosmer and Lemeshow 1989) using 
joint indicator terms for genotype only, 
for PAH measure only, and for both gen-
otype and PAH measure (Tables 3 and 4). 
Interaction contrast ratios (ICRs) and their 
95% CIs were calculated to measure the rela-
tive excess risk due to interaction (Assmann 
et al. 1996; Rothman and Greenland 1998). 
We also considered other categorizations of 
smoking exposure status that incorporated 
information collected by the questionnaire 
on environmental tobacco smoke (Gammon 
et al. 2004a), but the cell sizes were too small 
to yield meaningful results, so we do not show 
these data.
For our second set of analyses, our goal 
was to determine the association between 
PAH–DNA adducts and the GST variant 
alleles among control women only. We used 
unconditional logistic regression with detect-
able adducts as the dependent variable, and 
GSTs as the independent variable, controlling 
for age at reference and season of blood draw 
(Table 4). We also investigated the main effect 
of each genotype or number of variant alleles 
on the outcome of detectable PAH–DNA 
adducts in a multivariate model adjusted for 
age, smoking status, and season of blood draw. 
In a previous study (Shantakumar et al. 2005), 
we found that cigarette smoking was a sig-
nificant predictor of detectable PAH–DNA 
adducts among this population-based sample; 
thus, we also explored whether the GST geno-
types modified the association between smok-
ing status and detectable adducts. We also 
considered potential interactions with cigarette 
smoke because of its link to our biomarker, 
although we recognize that other PAH sources 
and other constituents of tobacco smoke could 
potentially interact with GST polymorphisms 
to affect risk; however, these other constitu-
ents of tobacco smoke have not been linked to 
breast cancer risk in a human study.
Results
Individual GSTs, PAHs, and breast cancer 
risk. As shown in Tables 1 and 2, we did not 
observe substantial effect modification, on 
a multiplicative or additive scale, by any of 
the individual genotypes on the associations 
between breast cancer risk and PAH exposure 
(PAH–DNA adducts or cigarette smoking).
Multiple GSTs and breast cancer risk. The 
ORs for the association between breast cancer 
risk and multiple GST variant alleles were 1.10 
(95% CI, 0.77–1.57) for three or more vari-
ants, 0.76 (95% CI, 0.56–1.03) for two vari-
ants, and 0.80 (95% CI, 0.59–1.08) for one 
variant. When we considered the combined 
effects of GSTM1, -P1, -T1, and -A1 variants 
that are coded based on their PAH-related 
biologic activity (rather than for their isothio-
cyanate-related activity), we did not find a 
significant association between the number of 
variant GST alleles and breast cancer risk.
Table 2. Age-adjusted ORs (95% CIs) for the individual GST genotypes on the associations between 
PAH–DNA adducts and breast cancer risk.
Genotype  PAH–DNA adducts  Cases (n)  Controls (n)  OR (95% CI)  p-Valuea
GSTT1
  Present  –  165  204  1.0  0.22
  +  463  474  1.01 (0.87–1.19)
  Null  –  40  61  0.68 (0.45–1.03)
  +  134  124  1.14 (0.87–1.48)
GSTM1
  Present  –  104  146  1.0  0.75
  +  301  320  0.99 (0.82–1.19)
  Null  –  100  114  0.93 (0.70–1.23)
  +  293  274  1.13 (0.93–1.37)
GSTP1
  AA (common)  –  107  133  1.0  0.77
  +  320  293  0.94 (0.78–1.13)
  AG or GG  –  106  153  0.83 (0.63–1.09)
  +  304  333  1.15 (0.95–1.38)
GSTA1
  A*/A*  –  75  111  1.0  0.53
  +  211  223  0.97 (0.78–1.20)
  A*/B* or B*/B*  –  145  179  0.83 (0.65–1.05)
  +  416  413  1.03 (0.86–1.22) 
Common alleles: GSTT1 present, GSTM1 present, GSTP1 (AA), GSTA1 (A*/A*). Variant alleles: GSTT1 null, GSTM1 null, 
GSTP1 (AG or GG), GSTA1 (A*/B* or B*/B*). Symbols: +, PAH–DNA adducts detected; –, PAH–DNA adducts not detected. 
aFrom likelihood ratio test.
Table 1. Age-adjusted ORs (95% CIs) for the individual GST genotypes on the associations between smok-
ing status and breast cancer risk.
Genotype  Smoking status  Cases (n)  Controls (n)  OR (95% CI)  p-Valuea
GSTT1
  Present  Never  351  341  1.0  0.27
    Ever  423  454  0.94 (0.80–1.11)
  Null  Never  97  112  0.97 (0.66–1.16)
    Ever  112  109  1.04 (0.78–1.37)
GSTM1
  Present  Never  227  247  1.0  0.62
    Ever  278  300  0.98 (0.81–1.19)
  Null  Never  218  201  1.14 (0.92–1.42)
    Ever  252  253  1.06 (0.86–1.29)
GSTP1
  AA (common)  Never  235  242  1.0  0.86
    Ever  275  309  0.91 (0.75–1.10)
  AG or GG  Never  239  234  1.04 (0.85–1.28)
    Ever  278  284  1.01 (0.83–1.22)
GSTA1
  A*/A* (common)  Never  145  168  1.0  0.60
    Ever  199  218  0.96 (0.77–1.20)
  A*/B* or B*/B*  Never  335  328  1.06 (0.88–1.28)
    Ever  362  376  1.02 (0.85–1.22) 
Common alleles: GSTT1 present, GSTM1 present, GSTP1 (AA), GSTA1 (A*/A*). Variant alleles: GSTT1 null, GSTM1 null, 
GSTP1 (AG or GG), GSTA1 (A*/B* or B*/B*).
aFrom likelihood ratio test.PAH–DNA adducts, GSTs, and breast cancer
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Multiple GSTs, PAHs, and breast can-
cer risk. Table 3 illustrates the potential joint 
effects of PAH–DNA adducts and the num-
ber of GST polymorphisms (one, two, or three 
or more variants) and breast cancer risk. We 
observed a 56% increase in risk (OR = 1.56; 
95% CI, 1.13–2.16) among women with 
detectable adducts and three or more GST 
variants [GSTT1 null variant, GSTM1 null 
variant, GSTP1 AG/GG genotype, GSTA1 
common (A*/B* or B*/B*) genotypes] com-
pared with those with all common genotypes 
and no detectable PAH–DNA adducts. The 
corresponding OR for three or more variants 
and no detectable adducts was 0.93 (95% CI, 
0.56–1.56). Women with one variant allele and 
no detectable adducts had a 44% reduced risk 
of breast cancer compared with women with all 
common alleles and no detectable adducts (OR, 
0.56; 95% CI, 0.40–0.77); the corresponding 
OR for detectable adducts was not significant 
(OR, 0.97; 95% CI, 0.78–1.20; Table 3).
As shown in Table 4, the ORs for the 
association between breast cancer risk and the 
number of GST variant alleles varied little with 
smoking status, and results for inter  action on 
either a multiplicative or additive scale were 
not statistically significant. For example, the 
OR associated with three or more GST vari-
ants was 1.18 among ever smokers (95% CI, 
0.82–1.69) but was 1.44 among never smok-
ers (95% CI, 0.97–2.14). Results for the inter-
action between multiple GST variants and 
pack-years of smoking (data not shown) are 
similar to those shown in Table 4.
When we categorized ever smokers by 
whether they were current or past smokers, 
the OR for the association between breast 
cancer risk and three or more GST vari-
ants was 0.62 (95% CI, 0.27–1.43) among 
current smokers, and 1.66 (95% CI, 0.93–
2.97) among past smokers, compared with 
never smokers with all four common alleles. 
However, the category sizes upon which 
these estimates are based were small (data not 
shown), and the p-value for the interaction on 
a multiplicative scale was 0.31.
GSTs, smoking, and PAH–DNA adducts 
among control women. We did not observe 
a significant association between any single 
GSTT1, GSTM1, GSTP1, or GSTA1 poly-
morphism and detectable PAH–DNA adducts 
among the control women (GSTT1: OR, 
1.09; 95% CI, 0.77–1.56; GSTM1: OR, 0.93; 
95% CI, 0.69–1.25; GSTP1: OR, 0.95; 95% 
CI, 0.72–1.27; GSTA1: OR, 1.15; 95% CI, 
0.86–1.53) or the number of variant geno-
types and detectable PAH–DNA adducts (one 
variant compared with all common alleles: 
OR, 1.60; 95% CI, 0.92–2.79; two vari-
ants compared with all common alleles: OR, 
1.35; 95% CI, 0.77–2.36; three or more vari-
ants compared with all common alleles: OR, 
1.45; 95% CI, 0.75–2.82). Table 5 shows the 
Table 5. Age-adjusted ORs (95% CIs) for the joint effect of GST polymorphisms and smoking on the out-
come of detectable PAH–DNA adducts among control women.
  Smoking  Adducts  Adducts       
  status  not detected  present  OR (95% CI)  p-Valuea  ICR (95% CI)
Genotype
  GSTT1
  Present  Never  99  197  1.0  0.20  –0.37 (–1.04 to 0.31)
  Ever  105  277  0.73 (0.53 to 0.99)
  Null  Never  37  60  1.18 (0.74 to 1.87)
  Ever  24  64  0.72 (0.43 to 1.20)
  GSTM1 
  Present  Never  78  140  1.0  0.76  0.10 (–0.26 to 0.46)
  Ever  68  180  0.65 (0.45 to 0.93)
  Null  Never  56  115  0.85 (0.57 to 1.26)
  Ever  58  159  0.64 (0.43 to 0.93)
  GSTP1
  AA (common)  Never  73  143  1.0  0.18  –0.28 (–1.10 to 0.62)
  Ever  80  190  0.96 (0.69 to 1.34)
  AG or GG  Never  75  125  1.29 (0.88 to 1.91)
  Ever  58  168  1.05 (0.72 to 1.52)
  GSTA1
  A*/A* (common)  Never  97  180  1.0  0.41  –0.17 (–0.96 to 0.89)
  Ever  82  233  0.67 (0.47 to 0.96)
  A*/B* or B*/B*  Never  54  97  1.07 (0.71 to 1.62)
  Ever  57  126  0.85 (0.57 to 1.26)
No. of variants
  Four common  Never  9  24  1.0  0.13  Referent
  Ever  11  44  0.54 (0.26 to 1.15)
  One variant  Never  59  97  1.26 (0.78 to 2.03)
  Ever  53  122  0.88 (0.55 to 1.42)    0.28 (–0.39 to 0.45)
  Two variants  Never  48  96  1.06 (0.65 to 1.75)
  Ever  45  126  0.74 (0.45 to 1.21)    –0.09 (–0.57 to 0.38)
  Three variants  Never  16  27  1.15 (0.56 to 2.35)
  Ever  15  39  0.79 (0.39 to 1.58)    0.18 (–0.23 to 0.59)
We adjusted data for age at reference and for season of blood draw. Common alleles: GSTT1 present, GSTM1 present, 
GSTP1 (AA), GSTA1 (A*/A*). Variant alleles: GSTT1 null, GSTM1 null, GSTP1 (AG or GG), GSTA1 (A*/B* or B*/B*).
aFrom likelihood ratio test.
Table 3. Age-adjusted ORs (95% CIs) for the effects of number of variant genotypes, PAH–DNA adducts, 
and risk of breast cancer.
No. of  PAH–DNA 
variants  adduct status  Cases (n)  Controls (n)  OR (95% CI)  p-Valuea  ICR (95% CI)
Four common  –  28  20  1.00 
  +  72  68  1.01 (0.71 to 1.43)    Referent
One variant  –  64  112  0.56 (0.40 to 0.77)  0.05
  +  215  219  0.97 (0.78 to 1.20)    0.60 (0.23 to 0.97)
Two variants  –  74  93  0.78 (0.56 to 1.07)  0.18
  +  183  222  0.82 (0.66 to 1.03)    0.36 (–0.12 to 0.84)
Three variants  –  29  31  0.93 (0.56 to 1.56)  0.43
  +  105  66  1.56 (1.13 to 2.16)    0.75 (0.20 to 1.30)
Common alleles: GSTT1 present, GSTM1 present, GSTP1 (AA), GSTA1 (A*/A*). Variant alleles: GSTT1 null, GSTM1 null, 
GSTP1 (AG or GG), GSTA1 (A*/B* or B*/B*). Symbols: +, PAH–DNA adducts detected; –, PAH–DNA adducts not detected. 
aFrom likelihood ratio test.
Table 4. Age-adjusted ORs (95% CIs) for the effect of number of variant genotypes, smoking status, and 
risk of breast cancer.
  Smoking  Cases  Controls 
No. of variants  status   (n)   (n)  Total  OR (95% CI)  p-Valuea  ICR (95% CI)
Four common  Never  58  39  97  1.0
  Ever  65  66  131  0.98 (0.67 to 1.43)  0.24  Referent
One variant  Never  162  177  339  0.96 (0.73 to 1.25)
  Ever  188  204  392  0.91 (0.71 to 1.18)  0.66  0.30 (–0.13 to 0.72)
Two variants  Never  139  164  303  0.89 (0.68 to 1.18)
  Ever  179  204  383  0.88 (0.68 to 1.14)  0.52  0.32 (–0.10 to 0.73)
Three or more variants  Never  70  51  121  1.44 (0.97 to 2.14)
  Ever  82  68  150  1.18 (0.82 to 1.69)  0.62  0.15 (–0.47 to 0.77)
Common alleles: GSTT1 present, GSTM1 present, GSTP1 (AA), GSTA1 (A*/A*). Variant alleles: GSTT1 null, GSTM1 null, 
GSTP1 (AG or GG), GSTA1 (A*/B* or B*/B*).
aFrom likelihood ratio test.McCarty et al.
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association between GST polymorphisms and 
PAH–DNA adducts among control women 
stratified by smoking status. Women who ever 
smoked and had the GSTM1 present genotype 
had a 35% reduced odds (OR, 0.65; 95% CI, 
0.45–0.93) of having detectable PAH–DNA 
adducts compared with never smokers with 
the same genotype. We noted similar results 
for ever smokers with the GSTM1 null geno-
type compared with never smokers with 
the GSTM1 common genotype (OR, 0.64; 
95% CI, 0.43–0.93). Ever smokers with the 
GSTT1 present genotype had a 27% reduced 
odds of PAH–DNA adducts (OR, 0.73; 95% 
CI, 0.53–0.99) compared with never smokers 
with the same genotype. Ever smokers with 
the common GSTA1 genotype had a reduced 
odds of PAH–DNA adducts compared with 
never smokers with the same genotype (OR, 
0.67; 95% CI, 0.47–0.96; Table 5). We found 
no evidence of effect modification between any 
of the individual genotypes and smoking sta-
tus on PAH–DNA adduct status on the mul-
tiplicative scale (LRT p-values: GSTT1, 0.20; 
GSTM1, 0.75; GSTP1, 0.15; GSTA1, 0.40) or 
on the additive scale. We did not find statisti-
cal evidence between number of variant alleles 
and smoking status on the odds of developing 
detectable PAH–DNA adducts on the addi-
tive scale (one-variant allele: ICR, 0.28; 95% 
CI, –0.39 to 0.45; two-variant alleles: ICR, 
–0.091; 95% CI, –0.57 to 0.38; three or more 
variant alleles: ICR, 0.177; 95% CI, –0.23 to 
0.59) or on the multiplicative scale (p-value 
from the LRT = 0.13). When considering the 
number of adducts as a continuous outcome 
(data not shown), we found no evidence of a 
main effect of the individual genotypes on the 
number of adducts in an age-adjusted model 
(GSTT1 p = 0.86, GSTM1 p = 0.54, GSTP1 
p = 0.91, GSTA1 p = 0.86).
Discussion
To the best of our knowledge, this is the first 
epidemiologic investigation of breast can-
cer to consider the joint effects of four GST 
polymorphisms and several measures of PAH 
exposure, including a PAH–DNA adduct 
biomarker. Despite the biologic plausibility 
of our hypothesis, we found no strong evi-
dence for an interaction between the number 
of variant GST alleles with various measures 
of PAH exposure (including ever/never smok-
ing status, pack-years of smoking, or detected 
PAH–DNA adducts) and breast cancer risk, 
nor did we find an association among the 
control women between number of variant 
GST polymorphisms and the outcome of 
detectable PAH–DNA adducts. We found 
some evidence for a reduced risk of detectable 
adducts among control women who were ever 
smokers regardless of whether they had the 
GSTM1 deletion polymorphism or the pres-
ent genotype (Table 5). We also report for 
the first time that among controls with the 
A*/A* GSTA1 genotype, ever smokers had 
lower odds of having detectable PAH–DNA 
adducts than did never smokers with the same 
genotype (OR, 0.62; 95% CI, 0.41–0.92).
GST polymorphisms and breast cancer 
risk. A few previous studies (Helzlsouer et al. 
1998; van der Hel et al. 2005) including our 
own have found that individual polymor-
phisms in GSTA1 (Ahn et al. 2006), GSTM1 
null (Helzlsouer et al. 1998; Spurdle et al. 
2007), and GSTT1 null (van der Hel et al. 
2005) and GSTP1 (heterozygote or homozy-
gote valine) (Helzlsouer et al. 1998) are mod-
estly associated with breast cancer, although 
others have reported no association with 
GSTT1 (García-Closas et al. 1999; Helzlsouer 
et al, 1998; Vogl et al. 2004), GSTP1 (Vogl 
et al. 2004), or GSTM1 (Ambrosone et al. 
1995; García-Closas et al. 1999; Vogl et al. 
2004). Effects of multiple combinations of 
GST polymorphisms on breast cancer risk 
have previously been conducted in smaller 
studies, with conflicting findings (Helzlsouer 
et al. 1998; Steck et al. 2007b; van der Hel 
et al. 2005; Vogl et al. 2004). Combined effect 
of all three GSTT1, GSTM1, and GSTP1 vari-
ants have been reported to have greater than a 
3-fold increase in breast cancer risk compared 
with women with the common genotype for 
all three polymorphisms (Helzlsouer et al. 
1998; Steck et al. 2007b). In this analysis, in 
which we considered the combined effects of 
the GSTT1, -M1, -P1, and -A1 variants that 
are coded based on their PAH-related biologic 
activity (rather than for their isothiocyanate-
related activity), we did not find a significant 
association between the number of variant 
GST alleles and breast cancer risk.
GST polymorphisms, PAHs, and breast 
cancer. Previous studies have differed on 
whether GST polymorphisms modify the 
association between cigarette smoking and 
breast cancer risk (Millikan et al. 2000; Terry 
and Goodman 2006; van der Hel et al. 2005; 
Vogl et al. 2004; Zheng et al. 2002). Smaller 
studies have reported that smoking did not 
modify associations between GSTT1 (Vogl 
et al. 2004), GSTM1 (van der Hel et al. 2005; 
Vogl et al. 2004), or GSTP1 polymorphisms 
(Vogl et al. 2004) and breast cancer, whereas 
former smokers with GSTT1 null were found 
to have an increased risk of breast cancer com-
pared with never smokers with GSTT1 present 
(van der Hel et al. 2005). For example, one 
recent breast cancer meta-analysis reported 
no interaction between individual GST poly-
morphisms and smoking, whereas another 
meta-analysis reported positive associations 
between breast cancer risk and GSTT1 present 
and GSTM1 null genotypes among smok-
ers (Terry and Goodman 2006; Vogl et al. 
2004). In contrast, we observed an increased 
risk of breast cancer with three or more variant 
GST alleles in a previous analysis (Steck et al. 
2007b), but no increased risk with number 
of variant alleles as defined by low PAH-
metabolizing activity, and no evidence of 
gene–environment interaction with PAH 
exposure. Our present findings are unique in 
that we investigated four GST polymorphisms 
simultaneously in a single large study.
To the best of our knowledge, this is the 
first study to examine the interaction between 
PAH–DNA adducts and individual/com-
bined effects of GSTA1, GSTM1, GSTP1, and 
GSTT1 genotypes on breast cancer risk. We 
found no pronounced adverse effect for the 
genotype–PAH exposure interaction, regardless 
of the PAH measure. Given that the genetic 
polymorphisms we examined are known to 
be functionally associated with deactivation of 
the active intermediates of PAHs, our findings 
are not easily interpreted. It is possible that the 
PAH–DNA adduct biomarker effect estimates 
already reflect any effects associated with meta-
bolic variation; however, if this were true, then 
any apparent interaction between PAHs and 
GSTs should have been evident when examin-
ing the joint effects with smoking. We found a 
reduction in risk among women with at least 
one variant allele and no detectable adducts, 
but we did not find a similar reduction among 
these same women in relation to no smok-
ing. Thus, we do not report evidence that 
PAHs interacted with these polymorphisms to 
  further increase risk.
We acknowledge that expression of GSTs 
can be modulated by a variety of factors, 
including diet. There is extensive literature on 
animal studies demonstrating an interaction 
between isothiocyanates and PAHs on cancer 
risk, and the induction of phase II enzymes 
by isothiocyanates (Hecht 1996, 2000). The 
interaction between GSTs and isothiocyanates 
does not appear to interact to affect breast 
cancer risk in humans or the variations in the 
urinary metabolites of isothiocyanates in our 
data (Steck et al. 2007a, 2007b). Whether 
cruciferous vegetable intake would further 
interact with PAHs and GSTs to affect breast 
cancer risk is unclear. Unfortunately, this 
study was underpowered to explore such three 
way interactions despite a large sample size. 
Nevertheless, it may be theoretically possi-
ble that breast cancer risk is influenced by a 
potential three-way interaction of PAH–DNA 
adducts, GST polymorphisms, and crucifer-
ous vegetable intake, although our current 
available data do not support this hypothesis 
(Steck et al. 2007a, 2007b).
GST polymorphisms, smoking, and PAH–
DNA adducts among control women. We 
considered the PAH–DNA adduct outcome 
as both a continuous and a dichotomous vari-
able (detected/not detected), although the lat-
ter may be more informative given the lack of 
a dose–response relationship between adducts PAH–DNA adducts, GSTs, and breast cancer
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and breast cancer risk (Gammon et al. 2002b). 
In our analyses among control women, indi-
vidual GSTT1, GSTM1, GSTP1, and GSTA1 
genotypes were not associated with detectable 
PAH–DNA adducts, nor was the number 
of variant GST alleles. Even after stratifica-
tion on smoking, the number of variant GST 
alleles was not associated with detectable 
PAH–DNA adducts; however, ever smok-
ers with either the GSTM1 null or GSTM1 
present genotype had a reduced risk of detect-
able PAH–DNA adducts (Table 5). We 
observed a similar finding within the strata 
of ever smokers and the GSTP1 common 
genotype compared with never smokers with 
the common genotype. Our results are the 
first published findings regarding GSTA1 
polymorphisms and PAH–DNA adducts. 
Our findings related to polymorphisms in 
GSTM1 and PAH–DNA adduct formation 
are in contrast with one study (Rundle et al. 
2003), while being consistent with others that 
report no significant difference in detectable 
PAH–DNA adducts based on GSTM1 status 
(Grinberg-Funes et al. 1994; Rothman et al. 
1995; Weiserbs et al. 2003). However, the 
LIBCSP results reported here are based upon 
a much larger sample size than previous anal-
yses, which yields more stable effect estimates. 
Additionally, we used different methods to 
measure the PAH–DNA adducts in the vari-
ous studies, possibly influencing the results.
Methodological considerations. In an epi-
demiologic study, the use of a biomarker of 
exposure, such as PAH–DNA adducts, is con-
sidered superior because exposure assessment 
is not based on self-report, eliminating con-
cerns for recall bias. Reliability in the meas-
urement of genotype and adducts was high. 
Measurement error was possible, although 
unlikely with genotyping and analysis of 
adducts; however, because the laboratory was 
blinded to status of samples, any measure-
ment error in measuring genotype and of 
PAH–DNA adduct status was independent of 
case–control status. Therefore, any resulting 
bias would have been nondifferential.
Our study power was limited when we 
examined interactions within subgroups 
of women, such as those with PAH–DNA 
adducts. However, the LIBCSP is the largest 
study conducted to date with information on 
PAH–DNA adducts with which to evaluate 
these associations, and thus our study power 
was better than that of previously reported 
studies.
We selected the GST polymorphisms 
because of their role in phase II metabolism, 
specifically metabolism of PAH-reactive inter-
mediates. Because PAH–DNA adducts may be 
related to inherited differences in the metabo-
lism of PAHs, this pathway was hypothesized to 
be important in individual breast cancer suscep-
tibility. GSTP1 and GSTM1 have been shown 
to have a role in detoxification of PAH carci-
nogenic intermediates produced by cytochrome 
P450 in phase I metabolism (Butkiewicz et al. 
2000). GSTT1 and GSTA1 have also been 
implicated in the metabolism of PAH inter-
mediates (Garte et al. 2007; Hayes and Pulford, 
1995; Korashy and El-Kadi 2006).
Conclusion
Our previous analyses have shown that breast 
cancer risk was modestly elevated in rela-
tion to PAH–DNA adducts (Gammon et al. 
2002b, 2004b), among certain subgroups of 
smokers (Gammon et al. 2004a), and among 
women with multiple variant alleles in GST 
genes (Steck et al. 2007b). In this analysis, 
however, we did not find strong evidence for 
further elevation of breast cancer risk, either 
on a multiplicative or on an additive scale, 
when we considered the joint effect of mul-
tiple GSTs and PAHs (cigarette smoking or 
PAH–DNA adducts), despite the biologic 
plausibility of such an interaction. These find-
ings are based upon the largest population-
based study of breast cancer conducted to date 
with a biomarker of PAH exposure. Further 
study may be warranted incorporating other 
biologic measures of PAH metabolism.
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